Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02293096 · ClinicalTrials.gov registry record · NA
Pharmacogenetic Prediction of Metoprolol Effectiveness
A NA study, sponsored by University of Colorado, Denver.
- Terminated
- Registry status
- NA
- Development phase
- 462
- Enrollment target
NCT02293096 is a NA study that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 462 participants.
The verdict
NCT02293096, a NA study, was terminated before completion, sponsored by University of Colorado, Denver.
- TERMINATED
- Registry status
- NA
- Development phase
- 462 participants
- Enrollment target
Study Summary
The investigators will prospectively follow a population of patients with uncontrolled high blood pressure beginning metoprolol succinate therapy to determine the drug effect in an observational clinical trial. The investigators will determine each individual's genotype for both CYP2D6 and Adrenoceptor Beta 1 (ADRB1). Metabolomic markers will be identified to determine if specific metabolites are associated with drug response. The investigators' overall objective is to determine if genetics predicts metoprolol succinate response better than clinical factors such as age, race, body mass index, dose, and medication co-ingestion.
Interventions
- GENETIC Genotyping
- DRUG metoprolol succinate
- PROCEDURE CYP2D6 Phenotyping
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 462 participants |
| Start Date | 2014-09 |
| Est. Completion | 2017-08-23 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02293096
The ClinicalTrials.gov registry entry for NCT02293096 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 462 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Genotyping is the first listed.
NCT02293096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02293096 about?
NCT02293096 is a clinical study titled "Pharmacogenetic Prediction of Metoprolol Effectiveness". The investigators will prospectively follow a population of patients with uncontrolled high blood pressure beginning metoprolol succinate therapy to determine the drug effect in an observational clinical trial. The investigators will determine each individual's genotype for both CYP2D6 and Adrenocep...
What is the current status of trial NCT02293096?
This trial is currently terminated. It is a NA study. The enrollment target is 462 participants. The study started on 2014-09. Estimated completion is 2017-08-23.
What interventions are being tested in trial NCT02293096?
The interventions under investigation include: Genotyping (GENETIC), metoprolol succinate (DRUG), CYP2D6 Phenotyping (PROCEDURE).
Who is sponsoring clinical trial NCT02293096?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.